Stockreport

SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort [Yahoo! Finance]

ASX LTD UNSP/ADR  (ASXFY) 
NASDAQ:AMEX Investor Relations: asx.com.au/about/investor-relations.htm
PDF The Safety Review Committee (SRC) assessed early data from the first 3 participants in cohort 4 who received 2 doses of Cu-SAR-bisPSMA. Two of these participants had co [Read more]